Search

Your search keyword '"Akkoc, Nurullah"' showing total 383 results
Start Over Author "Akkoc, Nurullah" Language english
383 results on '"Akkoc, Nurullah"'

1. Assessing safety and efficacy of TNFi treatment in late onset ankylosing spondylitis: a TURKBIO registry study

Author

Uslu, Sadettin, Gulle, Semih, Sen, Gercek, Cefle, Ayse, Yilmaz, Sema, Kocaer, Sinem Burcu, Yuce Inel, Tuba, Koca, Suleyman Serdar, Yolbas, Servet, Ozturk, Mehmet Akif, Senel, Soner, Inanc, Nevsun, Dalkilic, Huseyin Ediz, Soysal Gunduz, Ozgul, Tufan, Abdurrahman, Akar, Servet, Birlik, Ahmet Merih, Sari, Ismail, Akkoc, Nurullah, and Onen, Fatos

Published
2024
Full Text
View/download PDF

2. Influence of gender on Behçet's disease phenotype and irreversible organ damage: Data from the International AIDA Network Behçet's Disease Registry

Author

Sota, Jurgen, Ragab, Gaafar, AlMaglouth, Ibrahim, Lopalco, Giuseppe, Tufan, Abdurrahman, Direskeneli, Haner, Hinojosa-Azaola, Andrea, Mayrink Giardini, Henrique Ayres, Guerriero, Silvana, Triaggianese, Paola, Sfikakis, Petros P., Piga, Matteo, Ruscitti, Piero, Govoni, Marcello, Iagnocco, Annamaria, Carubbi, Francesco, Hernández-Rodríguez, José, Laymouna, Ahmed Hatem, Mahmoud, Ayman Abdel-Monem Ahmed, Ghanema, Mahmoud, Aboabat, Aos A., Asfina, Kazi Nur, Alanazi, Fehaid, Morrone, Maria, Spedicato, Veronica, Kucuk, Hamit, Kardas, Riza, Alibaz Öner, Fatma, Sevik, Gizem, Torres-Ruiz, Jiram, Kawakami-Campos, Perla Ayumi, Parente de Brito Antonelli, Isabelle, Dammacco, Rosanna, Chimenti, Maria Sole, Arida, Katerina, Floris, Alberto, Gentile, Martina, Ruffilli, Francesca, Bellis, Elisa, Alunno, Alessia, Espinosa, Gerard, Gentileschi, Stefano, Gaggiano, Carla, Vitale, Antonio, Caggiano, Valeria, Lopez, Roberta, Tarsia, Maria, Monti, Sara, Hatemi, Gülen, Karakoç, Alican, Frassi, Micol, Giacomelli, Roberto, Tharwat, Samar, Thabet, Maissa, Ciccia, Francesco, Emmi, Giacomo, Viapiana, Ombretta, Şahin, Ali, Sebastiani, Gian Domenico, Batu, Ezgi Deniz, Ozen, Seza, Sener, Seher, Opris-Belinski, Daniela, Costi, Stefania, Conforti, Alessandro, Cattalini, Marco, Bartoloni, Elena, Akkoç, Nurullah, Gunduz, Ozgul Soysal, Conti, Giovanni, Maier, Armin, Giardina, Annarita, Li Gobbi, Francesca, Parronchi, Paola, Sarzi Puttini, Piercarlo, Breda, Luciana, De Paulis, Amato, Carreño, Ester, La Torre, Francesco, Więsik-Scewczyk, Ewa, de-la Torre, Alejandra, Mejía-Salgado, Germán, Shahram, Farhad, Guiducci, Serena, Maggio, Maria Cristina, Aragona, Emma, Rigante, Donato, Ciavarro, Alessandro, Önen, Fatos, Erten, Şükran, Insalaco, Antonella, Del Giudice, Emanuela, Barone, Patrizia, Gicchino, Francesca, Brucato, Antonio, Lo Gullo, Alberto, Mauro, Angela, Karamanakos, Anastasios, Balistreri, Alberto, Mazzei, Maria Antonietta, Frediani, Bruno, Fabiani, Claudia, and Cantarini, Luca

Published
2024
Full Text
View/download PDF

3. Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration

Author

Ørnbjerg, Lykke M., Linde, Louise, Georgiadis, Stylianos, Rasmussen, Simon H., Lindström, Ulf, Askling, Johan, Michelsen, Brigitte, Giuseppe, Daniela Di, Wallman, Johan K., Pavelka, Karel, Závada, Jakub, Nissen, Michael J., Jones, Gareth T., Relas, Heikki, Pirilä, Laura, Tomšič, Matija, Rotar, Ziga, Geirsson, Arni Jon, Gudbjornsson, Bjorn, Kristianslund, Eirik K., van sder Horst-Bruinsma, Irene, Loft, Anne Gitte, Laas, Karin, Iannone, Florenzo, Corrado, Addolorata, Ciurea, Adrian, Santos, Maria J., Santos, Helena, Codreanu, Catalin, Akkoc, Nurullah, Gunduz, Ozgul S., Glintborg, Bente, Østergaard, Mikkel, and Hetland, Merete Lund

Published
2022
Full Text
View/download PDF

5. Does obesity affect treatment response to secukinumab and survival in ankylosing spondylitis? Real-life data from the TURKBIO Registry.

Author

Karaka, Ali, Gulle, Semih, Can, Gerçek, Dalkilic, Ediz, Akar, Servet, Koca, Suleyman Serdar, Pehlivan, Yavuz, Senel, Soner, Tufan, Abdurrahman, Ozturk, Mehmet Akif, Yilmaz, Sema, Yazici, Ayten, Cefle, Ayse, Inel, Tuba Yüce, Erez, Yesim, Sari, Ismail, Birlik, Merih, Direskeneli, Haner, Akkoc, Nurullah, and Onen, Fatos

Subjects
ANKYLOSING spondylitis, OBESITY, BODY mass index, BIOLOGICAL databases, SPONDYLOARTHROPATHIES
Abstract

Objectives: The aim of this study was to evaluate the impact of obesity on the treatment response to secukinumab and drug survival rate in patients with ankylosing spondylitis (AS). Methods: We performed an observational cohort study that included AS patients based on the biological drug database in Turkey (TURKBIO) Registry between 2018 and 2021. The patients were divided into three groups: normal [body mass index (BMI) < 25 kg/m2], overweight (BMI: 25–30 kg/m2), and obese (BMI ≥ 30 kg/m2). Disease activity was evaluated at baseline, 3, 6, and 12 months. Drug retention rates at 12 months were also investigated. Results: There were 166 AS patients using secukinumab (56.6% male, mean age: 44.9 ± 11.6 years). The median follow-up time was 17.2 (3–33.2) months. Forty-eight (28.9%) patients were obese. The mean age was higher in the obese group than in others (P = .003). There was no statistically significant difference in Bath Ankylosing Spondylitis Disease Activity Index 50, Assessment of SpondyloArthritis international Society 20 (ASAS20), ASAS40, Ankylosing Spondylitis Disease Activity Score (ASDAS) low disease activity, and ASDAS clinically important improvement responses between the three groups at 3, 6, and 12 months, although they were numerically lower in obese patients. Drug retention rates at 12 months were similar in all groups (P > .05). Conclusions: This study suggested that obesity did not affect secukinumab treatment response and drug retention in AS patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Does obesity affect treatment response to secukinumab and survival in ankylosing spondylitis? Real-life data from the TURKBIO Registry

Author

Akkoc, Nurullah, PEHLİVAN, YAVUZ, Senel, Soner, TUFAN, ABDURRAHMAN, ÖZTÜRK, MEHMET AKİF, SARI, İSMAİL, Yilmaz, Sema, Koca, Suleyman Serdar, Akar, Servet, Yazici, Ayten, Cefle, Ayse, DALKILIÇ, HÜSEYİN EDİZ, Inel, Tuba Yuce, Erez, Yesim, Birlik, Merih, Direskeneli, Haner, Karakas, Ali, Onen, Fatos, CAN, GÜNAY, and Gulle, Semih

Abstract

Objectives The aim of this study was to evaluate the impact of obesity on the treatment response to secukinumab and drug survival rate in patients with ankylosing spondylitis (AS). Methods We performed an observational cohort study that included AS patients based on the biological drug database in Turkey (TURKBIO) Registry between 2018 and 2021. The patients were divided into three groups: normal [body mass index (BMI) < 25 kg/m(2)], overweight (BMI: 25-30 kg/m(2)), and obese (BMI & GE; 30 kg/m(2)). Disease activity was evaluated at baseline, 3, 6, and 12 months. Drug retention rates at 12 months were also investigated. Results There were 166 AS patients using secukinumab (56.6% male, mean age: 44.9 & PLUSMN; 11.6 years). The median follow-up time was 17.2 (3-33.2) months. Forty-eight (28.9%) patients were obese. The mean age was higher in the obese group than in others (P = .003). There was no statistically significant difference in Bath Ankylosing Spondylitis Disease Activity Index 50, Assessment of SpondyloArthritis international Society 20 (ASAS20), ASAS40, Ankylosing Spondylitis Disease Activity Score (ASDAS) low disease activity, and ASDAS clinically important improvement responses between the three groups at 3, 6, and 12 months, although they were numerically lower in obese patients. Drug retention rates at 12 months were similar in all groups (P > .05). Conclusions This study suggested that obesity did not affect secukinumab treatment response and drug retention in AS patients.

Published
2023

10. Corrigendum to ‘Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: data from the EuroSpA collaboration’ [Seminars in Arthritis and Rheumatism 56 (2022) 1-13/152081] (Seminars in Arthritis and Rheumatism (2022) 56, (S0049017222001329), (10.1016/j.semarthrit.2022.152081))

Author

Ørnbjerg, Lykke M., Linde, Louise, Georgiadis, Stylianos, Rasmussen, Simon H., Lindström, Ulf, Askling, Johan, Michelsen, Brigitte, Giuseppe, Daniela Di, Wallman, Johan K., Pavelka, Karel, Závada, Jakub, Nissen, Michael J., Jones, Gareth T., Relas, Heikki, Pirilä, Laura, Tomšič, Matija, Rotar, Ziga, Geirsson, Arni Jon, Gudbjornsson, Bjorn, Kristianslund, Eirik K., van der Horst-Bruinsma, Irene, Loft, Anne Gitte, Laas, Karin, Iannone, Florenzo, Corrado, Addolorata, Ciurea, Adrian, Santos, Maria J., Santos, Helena, Codreanu, Catalin, Akkoc, Nurullah, Gunduz, Ozgul S., Glintborg, Bente, Østergaard, Mikkel, Hetland, Merete Lund, Rheumatology, AII - Infectious diseases, AII - Inflammatory diseases, AMS - Musculoskeletal Health, and AMS - Tissue Function & Regeneration

Abstract

The authors regret that the following incorrect values have been published in the original paper: In the abstract: Line 11-12: “age, per year: 0.97 (0.97-0.98)” should be “age, per year: 0.98 (0.97-0.99)” Line 12: “men vs. women: 1.88 (1.60-2.22)” should be “men vs. women: 1.79 (1.51-2.12)” Line 12: “current vs. non-smoking: 0.76 (0.63-0.91)” should be “current vs. non-smoking: 0.72 (0.59-0.87)” Line 12-13: “HLA-B27 positive vs. negative: 1.51 (1.20-1.91)” should be “HLA-B27 positive vs. negative: 1.65 (1.27-2.15)” Line 14: “CRP>10 vs. ≤10 mg/l: 1.49 (1.25-1.77)” should be “CRP>10 vs. ≤10 mg/l: 1.36 (1.14-1.62)” Line 15-16: “fatigue and spinal pain: 0.99 (0.99-1.00) and 0.99 (0.99-1.99)” should be “fatigue and spinal pain: 0.99 (0.99-0.99) and 0.99 (0.99-1.00)” In Table 3, row with EPV (row 3 after header/subheader): Column with header/subheader “Czech Republic/ATTRA”: EPV 15.9 should be 13.2 Column with header/subheader “Netherlands/ARC”: EPV 1 should be 1.0 Column with header/subheader “Portugal/Reuma.pt”: EPV 14.7 should be 13.1 Column with header/subheader “Romania/RRBR”: EPV 2.8 should be 2.4 Column with header/subheader “Turkey/TURKBIO”: EPV 12.9 should be 11.8 In Table 5, row with “Patient global score, mm” (row 10 counting from row with “Age at treatment start, years”): In the column with header: “Analysis of 12-month drug retention” and subheader: “Univariate”, the value for the odds ratio (OR) is missing. The OR should be 0.99. The authors would like to apologise for any inconvenience caused.

Published
2023
Full Text
View/download PDF

11. The challenge of the definition of early symptomatic knee osteoarthritis: a proposal of criteria and red flags from an international initiative promoted by the Italian Society for Rheumatology

Author

Migliore, Alberto, Scirè, Carlo Alberto, Carmona, Loreto, Beaumont, Gabriel Herrero, Bizzi, Emanuele, Branco, Jaime, Carrara, Greta, Chevalier, Xavier, Collaku, Ledio, Aslanidis, Spiros, Denisov, Lev, Di Matteo, Luigi, Bianchi, Gerolamo, Diracoglu, Demirhan, Frediani, Bruno, Maheu, Emmanuel, Martusevich, Natalia, Bagnato, Gian Filippo, Scarpellini, Magda, Minisola, Giovanni, Akkoc, Nurullah, Ramonda, Roberta, Barskova, Tatiana, Babic-Naglic, Durda, Muelas, Jose Vicente Moreno, Ionescu, Ruxandra, Rashkov, Rasho, Damjanov, Nemanja, and Cerinic, Marco Matucci

Published
2017
Full Text
View/download PDF

13. Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration

Author

Ørnbjerg, Lykke Midtbøll, Linde, Louise, Georgiadis, Stylianos, Rasmussen, Simon H, Lindström, Ulf, Askling, Johan, Michelsen, Brigitte, Giuseppe, Daniela Di, Wallman, Johan K, Pavelka, Karel, Závada, Jakub, Nissen, Michael J, Jones, Gareth T, Relas, Heikki, Pirilä, Laura, Tomšič, Matija, Rotar, Žiga, Geirsson, Árni Jón, Gudbjornsson, Bjorn, Kristianslund, Eirik K, van Sder Horst-Bruinsma, Irene, Loft, Anne Gitte, Laas, Karin, Iannone, Florenzo, Corrado, Addolorata, Ciurea, Adrian, Santos, Maria J, Santos, Helena, Codreanu, Catalin, Akkoc, Nurullah, et al, and University of Zurich

Subjects
10051 Rheumatology Clinic and Institute of Physical Medicine, 610 Medicine & health
Published
2022
Full Text
View/download PDF

15. An Assessment in SpondyloArthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS

Author

Molto, Anna, Gossec, Laure, Meghnathi, Bhowmik, Landewé, Robert B M, van der Heijde, Désirée, Atagunduz, Pamir, Elzorkany, Bassel Kamal, Akkoc, Nurullah, Kiltz, Uta, Gu, Jieruo, Wei, James Cheng Chung, Dougados, Maxime, Molto, A, Gossec, L, Meghnathi, B, RLANDEWE, Der heijde, D Van, Atagunduz, P, Zorkany, B El, Akkoc, N, Kiltz, U, Gu, J, Wei, J Cheng-chung, Pandya, M Dougados,s, Navarro, V, Gaydukova, I, Geher, P, Spoorenberg, A, Aydin, S, Pimentel, F, Kishimoto, M, Gallen, F Van, Collantes-estevez, E, Schiotis, R, Marzo-ortega, H, O’shea, B, Ramos-remus, C, and Magrey, And M

Published
2018
Full Text
View/download PDF

17. Bilateral Paraneoplastic Vitritis: A Case Report

Author

Yigitaslan, Ezgi Karatas, Ucan, Eyup Sabri, Akkoc, Nurullah, and Saatci, Ali Osman

Subjects
genetic structures, small-cell lung cancer, uveitis, Paraneoplastic syndrome, Case Report, vitritis, eye diseases, respiratory tract diseases
Abstract

This report describes the case of a patient who presented with bilateral vitritis that led to a diagnosis of small-cell lung cancer (SCLC). A 70-year-old man was examined due to bilateral gradual visual deterioration. Symmetrical vitritis was observed in both eyes with no evidence of other fundus pathology. The opthalmological diagnosis was bilateral paraneoplastic vitritis. The patient was an active smoker and had a short history of weight loss. A systemic evaluation resulted in a diagnosis of SCLC. The appropriate cancer treatment was provided, as well as a short-term oral steroid. The vitritis responded well to steroid treatment. Ocular manifestations can be an early sign of malignancy, and ophthalmologists should be aware of this possibility.

Published
2021

27. Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis

Author

Sepriano, Alexandre, Landewé, Robert, van der Heijde, Désirée, Sieper, Joachim, Akkoc, Nurullah, Brandt, Jan, Braun, Jürgen, Collantes-Estevez, Eduardo, Dougados, Maxime, Fitzgerald, Oliver, Huang, Feng, Gu, Jieruo, Kirazli, Yesim, Maksymowych, Walter P, Marzo-Ortega, Helena, Olivieri, Ignazio, Ozgocmen, Salih, Roussou, Euthalia, Scarpato, Salvatore, Sørensen, Inge J, Valle-Oñate, Rafael, Van den Bosch, Filip, van der Horst-Bruinsma, Irene, Weber, Ulrich, Wei, James, and Rudwaleit, Martin

Published
2016
Full Text
View/download PDF

28. Erratum to: The challenge of the definition of early symptomatic knee osteoarthritis: a proposal of criteria and red flags from an international initiative promoted by the Italian Society for Rheumatology

Author

Migliore, Alberto, Scirè, Carlo Alberto, Carmona, Loreto, Herrero-Beaumont, Gabriel, Bizzi, Emanuele, Branco, Jaime, Carrara, Greta, Chevalier, Xavier, Collaku, Ledio, Aslanidis, Spiros, Denisov, Lev, Di Matteo, Luigi, Bianchi, Gerolamo, Diracoglu, Demirhan, Frediani, Bruno, Maheu, Emmanuel, Martusevich, Natalia, Bagnato, Gian Filippo, Scarpellini, Magda, Minisola, Giovanni, Akkoc, Nurullah, Ramonda, Roberta, Barskova, Tatiana, Babic-Naglic, Durda, Muelas, Jose Vicente Moreno, Ionescu, Ruxandra, Rashkov, Rasho, Damjanov, Nemanja, and Cerinic, Marco Matucci

Published
2017
Full Text
View/download PDF

29. Identification of Susceptibility Loci in IL6, RPS9/LILRB3, and an Intergenic Locus on Chromosome 21q22 in Takayasu Arteritis in a Genome-Wide Association Study

Author

Renauer, Paul A., Saruhan-Direskeneli, Guher, Coit, Patrick, Adler, Adam, Aksu, Kenan, Keser, Gokhan, Alibaz-Oner, Fatma, Aydin, Sibel Z., Kamali, Sevil, Inanc, Murat, Carette, Simon, Cuthbertson, David, Hoffman, Gary S., Akar, Servet, Onen, Fatos, Akkoc, Nurullah, Khalidi, Nader A., Koening, Curry, Karadag, Omer, Kiraz, Sedat, Langford, Carol A., Maksimowicz-McKinnon, Kathleen, McAlear, Carol A., Ozbalkan, Zeynep, Ates, Askin, Karaaslan, Yasar, Duzgun, Nursen, Monach, Paul A., Ozer, Huseyin T. E., Erken, Eren, Ozturk, Mehmet A., Yazici, Ayten, Cefle, Ayse, Onat, Ahmet Mesut, Kisacik, Bunyamin, Pagnoux, Christian, Kasifoglu, Timucin, Seyahi, Emire, Fresko, Izzet, Seo, Philip, Sreih, Antoine G., Warrington, Kenneth J., Ytterberg, Steven R., Cobankara, Veli, Cunninghame-Graham, Deborah S., Vyse, Timothy J., Pamuk, Omer N., Tunc, Ercan S., Dalkilic, Ediz, Bicakcigil, Muge, Yentur, Sibel P., Wren, Jonathan D., Merkel, Peter A., Direskeneli, Haner, and Sawalha, Amr H.

Published
2015
Full Text
View/download PDF

30. impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis.

Author

Nissen, Michael, Delcoigne, Bénédicte, Giuseppe, Daniela Di, Jacobsson, Lennart, Hetland, Merete Lund, Ciurea, Adrian, Nekvindova, Lucie, Iannone, Florenzo, Akkoc, Nurullah, Sokka-Isler, Tuulikki, Fagerli, Karen Minde, Santos, Maria Jose, Codreanu, Catalin, Pombo-Suarez, Manuel, Rotar, Ziga, Gudbjornsson, Bjorn, van der Horst-Bruinsma, Irene, Loft, Anne Gitte, Möller, Burkhard, and Mann, Herman

Subjects
CLINICAL drug trials, REPORTING of diseases, C-reactive protein, COMBINATION drug therapy, CONFIDENCE intervals, META-analysis, ANTI-inflammatory agents, ANKYLOSIS, SPONDYLOARTHROPATHIES, ANTIRHEUMATIC agents, SYNTHETIC drugs, TREATMENT effectiveness, DESCRIPTIVE statistics, PATIENT compliance, LOGISTIC regression analysis, ODDS ratio, ARTHRITIS, DISEASE remission, EVALUATION
Abstract

Objectives Many axial spondylarthritis (axSpA) patients receive a conventional synthetic DMARD (csDMARD) in combination with a TNF inhibitor (TNFi). However, the value of this co-therapy remains unclear. The objectives were to describe the characteristics of axSpA patients initiating a first TNFi as monotherapy compared with co-therapy with csDMARD, to compare one-year TNFi retention and remission rates, and to explore the impact of peripheral arthritis. Methods Data was collected from 13 European registries. One-year outcomes included TNFi retention and hazard ratios (HR) for discontinuation with 95% CIs. Logistic regression was performed with adjusted odds ratios (OR) of achieving remission (Ankylosing Spondylitis Disease Activity Score (ASDAS)-CRP < 1.3 and/or BASDAI < 2) and stratified by treatment. Inter-registry heterogeneity was assessed using random-effect meta-analyses, combined results were presented when heterogeneity was not significant. Peripheral arthritis was defined as ≥1 swollen joint at baseline (=TNFi start). Results Amongst 24 171 axSpA patients, 32% received csDMARD co-therapy (range across countries: 13.5% to 71.2%). The co-therapy group had more baseline peripheral arthritis and higher CRP than the monotherapy group. One-year TNFi-retention rates (95% CI): 79% (78, 79%) for TNFi monotherapy vs 82% (81, 83%) with co-therapy (P  < 0.001). Remission was obtained in 20% on monotherapy and 22% on co-therapy (P  < 0.001); adjusted OR of 1.16 (1.07, 1.25). Remission rates at 12 months were similar in patients with/without peripheral arthritis. Conclusion This large European study of axial SpA patients showed similar one-year treatment outcomes for TNFi monotherapy and csDMARD co-therapy, although considerable heterogeneity across countries limited the identification of certain subgroups (e.g. peripheral arthritis) that may benefit from co-therapy. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results